Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease
Authors:
- 1 October 2025
- journal article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (10) , 1040
Abstract
Importance: Anti-IgLON5 disease is an autoimmune encephalopathy that often leads to severe disability or death. The efficacy of immunotherapy remains unknown.Objective: To investigate whether early immunotherapy is associated with disability and death in anti-IgLON5 disease.Design, Setting, and Participants: This retrospective, multicenter cohort study of patients with anti-IgLON5 disease was conducted from 2014 to 2024, with a median (IQR) follow-up of 66 (33-97) months after disease onset. Data from the German Network for Research on Autoimmune Encephalitis Registry, University Hospital Clinic of Barcelona (Spain), and Erasmus University Medical Center (the Netherlands) were analyzed. Eligibility criteria were clinical features consistent with anti-IgLON5 disease and the presence of IgLON5 antibodies in serum or cerebrospinal fluid. Data were collected by treating physicians using a structured questionnaire. Of 121 patients systematically selected from participating centers and registries, 14 patients were excluded due to insufficient clinical information or withdrawal of consent.Intervention: Initiation of immunotherapy based on the treating physician’s decision.Main Outcomes and Measures: Clinical disability was assessed using the modified Rankin Scale (mRS) at the most recent follow-up visit and the proportion of patients who died.Results: Among 107 patients with anti-IgLON5 disease (46 female [43.0%] and 61 male [57.0%]; median [IQR] age at the time of disease onset, 64 [57-70] years), 25 patients (23.4%) received immunotherapy during the first year of disease onset and 57 patients (53.3%) received it later. Among early treated patients, 9 individuals (36.0%) received intravenous immunoglobulins and 13 individuals (52.0%) received rituximab. A total of 44 patients (41.1%) died, and at least two-thirds of these deaths were related to anti-IgLON5 disease (28 patients [63.6%]). Early immunotherapy was the only modifiable independent factor associated with a lower long-term disability (odds ratio, 0.32; 95% CI, 0.13-0.83; P = .02) and survival (odds ratio, 2.70; 95% CI, 0.99-7.69; P = .047). Only intravenous immunoglobulin started within the first year of disease onset was associated with a lower median (IQR) mRS score at the most recent follow-up (2 [1-2.5] vs 3 [2-6]; P = .005; r = 0.55) and a lower proportion of deaths (0 of 9 patients vs 6 of 16 patients [37.5%]; P = .04) compared with other early immunotherapies despite a similar baseline mRS score.Conclusions and Relevance: In this study, early initiation of intravenous immunoglobulins (within the first year of onset) was associated with favorable long-term outcomes and improved survival in anti-IgLON5 disease. Larger prospective studies are needed to validate this finding.Keywords
This publication has 19 references indexed in Scilit:
- Clinical presentations and antibody mechanisms in anti-IgLON5 diseaseRevue Neurologique, 2024
- Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 diseaseActa Neuropathologica, 2023
- Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 diseaseBrain, 2022
- Anti-IgLON5 Disease2022
- Expanding the clinical spectrum of anti‐IgLON5 disease: A multicenter retrospective studyEuropean Journal of Neurology, 2021
- Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 diseaseJournal of Neurology, 2020
- Corticobasal Syndrome in a Patient with Anti‐IgLON5 AntibodiesMovement Disorders Clinical Practice, 2020
- Response to immunotherapy in anti‐IgLON5 disease: A systematic reviewActa Neurologica Scandinavica, 2019
- Neuropathological criteria of anti-IgLON5-related tauopathyActa Neuropathologica, 2016
- A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem studyThe Lancet Neurology, 2014